post PAE IPSS/QoL improvement persists post-RT

HOT OFF THE PRESS! Neoadjuvant PAE prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation - https://t.co/uk9rtTBJuO @MoffittNews @MoffittRadOnc @KOSJ12 @gdgrass @VaseemKhatri @ctRO_journal

Patients can benefit from SBRT / PBT over TACE in HCC (ineligible for upfront surgery/transplant) ! 🚨 Local Control HR 0.16 (0.08, 0.34) 🚨 💥 PFS HR 0.37 (0.23, 0.60) 💥 OS RR 0.79 (0.51, 1.22) Toxicity RR 0.86 (0.31, 2.37)

@Rrkotecha @Dr__Sree @DrReshmaMahtani @BrainTumorDoc Sasha Beyer @joshuapalmermd @aiims2738 @Nicole_O_W @KAhmedMD @MNMillsMD @celloradonc @JMBryantMD @NakashimaJustyn @DekuangZhao @ajayd0533

1. 🚫⬆️ risk of symptomatic RN (2.4% incidence per lesion @ 24 mo) 2. ⬇️ systemic PFS and distant intracranial control w/HER2Low 3. 💪 LC (97% @ 12 mo) Collab b/w @MoffittRadOnc @MiamiCancerInst and @OhioStateRadOnc

Our multi institution series on T-DXd and SRS for HER2+ and HER2 Low Brain Mets was just published in @Nature_NPJ Breast Cancer! https://t.co/NmreorGS6B

Thanks Dr. Ahmed @DrVogelbaum & @MoffittNews colleagues important addition to literature 1 yr LC 94% 44% SRS sessions concurrent, 56% delivered sequentially prior to tucatinib initiation Tucatinib is a HER2-targeted TKI Study particularly relevant w/common use HER2-CLIMB regimen

Is SRS WITH tucatinib for brain mets safe? Based on this study, Yes. · 135 lesions SRS · 4% symptomatic radiation necrosis https://t.co/ucJU5i7LjD

We cannot wait welcome our newest class of residents @MoffittNews! Congratulations to Emily Keit MD, Vaseem Khatri MD, and @NakashimaJustyn DO! #RadOnc #MatchDay2021 @JessicaFrakesMD @SA_Rosenberg